The Use of Atherogenic Index of Plasma in Assessing the Potential Cardiovascular Risk among ABO Blood Groups in Sickle Cell Disease Patients

Authors

  • Mathias Abiodun Emokpae University of Benin
  • Lynda Bose Akpologun University of Benin

DOI:

https://doi.org/10.18034/mjmbr.v4i2.431

Keywords:

ABO blood groups, atherogenic indices, cardiovascular disease, sickle cell disease

Abstract

Studies have associated ABO blood groups with cardiovascular risk events in the general population and no significant association has yet been reported in sickle cell disease (SCD) patients. This study uses the atherogenic indices to evaluate the potential cardiovascular disease (CVD) risk of ABO blood groups in SCD patients. Lipoprotein concentrations were assayed in 200 SCD patients and 100 control subjects with normal haemoglobin using the enzymatic colorimetric method. The atherogenic indices were calculated and compared among the various blood groups to show which of the blood group has elevated atherogenic risk of CVD. The means total cholesterol, triglycerides and low-density lipoprotein cholesterol levels were highest in blood group A and lowest in blood group O while high-density lipoprotein cholesterol level was lowest in blood group A and highest in blood group O. All the atherogenic indices were highest in blood group A and lowest in blood group O. The mean levels of lipoprotein variables and atherogenic indices were not significantly different between the blood group B and AB. Atherogenic index of plasma (AIP), cardiac risk ratio (CRR) and atherogenic coefficient (AC) correlated positively (r=0.348,p=0.005; r=0.236, p=0.05; r=0.238,p=0.05) respectively with blood group A. Similarly AIP, CRR and AC correlated positively (r=0.316, p=0.05; r=0.311, p=0.05; r=0.310, p=0.05) with blood group B. On the other hand, AIP and AC failed to correlate with blood group AB but CRR correlated (r=0.321, p=0.05) with blood group AB. All the atherogenic indices did not correlate significantly with blood group O. Atherogenic indices were higher in non-O blood groups than blood group O. Patients with non-O blood groups may require detail evaluations and closer monitoring than those with blood group O with respect to CVD risk.

 

Downloads

Download data is not yet available.

Author Biographies

  • Mathias Abiodun Emokpae, University of Benin

    Senior Lecturer, Department of Medical Laboratory Science, University of Benin, PMB 1154, NIGERIA

  • Lynda Bose Akpologun, University of Benin

    Intern, Department of Medical Laboratory Science, University of Benin, PMB 1154, NIGERIA

References

Amirzadegan A, Salarifar M, Sadeghian S, Davoodi G, Darabian C, Goodarzynejad H. Correlation between ABO blood groups, major risk factors and coronary artery disease. Int J Cardiol 2006; 110:256-258. DOI: https://doi.org/10.1016/j.ijcard.2005.06.058

Biswas S, Ghoshal PK, Halder B, Mandal N. Distribution of ABO blood group and major cardiovascular risk factors with coronary heart disease. BioMed Res Int 2013; 782941:1-5. DOI: https://doi.org/10.1155/2013/782941

Blaton V. The role of lipids in the development of atherosclerosis and coronary heart disease: guidelines for diagnosis and treatment. J Int Federat Clin Chem Lab Med 1997; 51:16-22.

Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-c) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo B-lipoprotein-depleted plasma (FERsubHDL). Clin Biochem 2001; 34:583-585. DOI: https://doi.org/10.1016/S0009-9120(01)00263-6

Eastlund T. The histo-blood group ABO system and tissue transplantation. Transfusion 1998; 38:975-988. DOI: https://doi.org/10.1046/j.1537-2995.1998.381098440863.x

Emokpae MA, Abdu A, Uadia PO, Borodo MM. Lipid profile in Sickle Cell Disease patients with Chronic Kidney Disease. Sahel Med J 2010; 13(1):20-23.

Emokpae MA, Arogundade A, Adumanya SC. Use of atherogenic index of plasma in evaluating the potential cardio protective effects of red wine consumption: Studies in Nigerian young adult volunteers. Biokemistri 2013; 25(3):118-123.

Erikssen J, Thaulow E, Stormorken H, Brendemoen O, Hellem A.ABO bllod groups and coronary heart disease (CHD). A study in subjects with severe and latent CHD. Thromb Haemost 1980; 43:137-140. DOI: https://doi.org/10.1055/s-0038-1650035

Fox MH, Webber LS, Thurmon TF, Berbenson GS. ABO blood group associations with cardiovascular risk factor variables. Hum Biol 1986; 58(4):549-584.

Franchini M, Capra F, Targher G, Montagnana M, Lippi G. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J. 2007; 5:14. DOI: https://doi.org/10.1186/1477-9560-5-14

Franchini M, Lippi G. The intriguing relationship between the ABO blood group, cardiovascular disease and cancer. BMC Med 2015; 13:7 DOI: https://doi.org/10.1186/s12916-014-0250-y

Friedewald WT, Levy RL, Fredrickson DS. Estimation of concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972; 10:499-502. DOI: https://doi.org/10.1093/clinchem/18.6.499

Gaudreault N, Kumar N, Posada JM et al. ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory molecules on monocytes and vascular endothelium. Arterioscler Thromb Vasc Biol 2012; 32(2):264-272. DOI: https://doi.org/10.1161/ATVBAHA.111.238964

He M, Wolpin B, Rexrode K, Manson JE, RimmE, Hu FB, Qi L. ABO blood group and Risk of coronary heart disease in two prospective cohort studies. Arterioscler Thromb Vasc Biol 2012; Doi 10.1161/ATVBAHA.112.248757. DOI: https://doi.org/10.1161/ATVBAHA.112.248757

Jenkens PV, O’Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006; 46(10):1836-1844. DOI: https://doi.org/10.1111/j.1537-2995.2006.00975.x

John D, Brunzell MD. Lipoprotein management in patients with cardiometabolic risk. J Am Coll Cardiol 2008; 51:1512-1524. DOI: https://doi.org/10.1016/j.jacc.2008.02.034

Nydegger UE, Wuillemin WA, Julmy F, Meyer BJ, Carrel TP. Association of ABO histo-blood B allele with myocardial infarction. Eur J Immunogenet 2003; 30:201-206. DOI: https://doi.org/10.1046/j.1365-2370.2003.00390.x

Platt D, Muhlberg W, Kiehl L, Schmitt-Ruth R. ABO blood group system, age, sex, risk factors and cardiac infarction. Arch Gerontol Geriatr 1985; 4:241-249. DOI: https://doi.org/10.1016/0167-4943(85)90006-8

Storry JR, Olsson ML. The ABO blood group system revisited: a review and update. Immunohematology 2009; 25(2):48-59.

Takeshi T, Keisuke N, Takaaki I, Makoto Y, Tatsuji N. Involvement of adhesion molecule in in-vitro plaque-like formation of macrophages stimulated with Aggregatibacter actinimycetemcomitans lipopolysaccharide. J Periodont Res 2010; 45(4):550-556.

Tariq M, Ali R. Comparative study for atherogenic index of plasma (AIP) in patients with type 1 Diabetes mellitus, type 2 Diabetes mellitus, thalassemia and Hypothyroidism. Int J Chem Res 2012; 02:10-14.

Tarjan Z, Tonelli M, Duba J, Zorandi A. Correlation between ABO and Rh blood groups, serum cholesterol and ischaemic heart disease in patients undergoing coronarography. Orv Hetil 1995; 136(15):767-769.

Wazirali H, Ashaque RA, Herzig JW. Association of blood group A with increased risk of coronary heart disease in the Pakistani population. Pak J Physiol 2005; 1(1-2):1-3.

Whincup PH, Cook DG, Phillips AN, Shaper AG. ABO blood group and ischaemic heart disease in British men. Br Med J 1990; 300:1679-1682. DOI: https://doi.org/10.1136/bmj.300.6741.1679

Zera E, Xinxo S, Hatellari A. The evaluation of Relationship between ABO blood groups and cardiovascular risk factors in patients with acute Myocardial infarction in Durres population. Saudi J Med Med Scis 2015; 3(1):40-43. DOI: https://doi.org/10.4103/1658-631X.149672

Zhang H, Mooney CJ, Reilly MP. ABO blood groups and Cardiovascular Diseases. Int J Vascular Med 2012; 1-11. DOI: https://doi.org/10.1155/2012/641917

-- 0 --

Downloads

Published

2017-12-31

Issue

Vol. 4 No. 2 (2017): July - December Issue

Section

Peer-reviewed Article

License

The CC BY-NC 4.0 license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge & be non-commercial, they don’t have to license their derivative works on the same terms.
|| View License Deed ||
|| View Legal Code ||
 
Publishing paper with the "Malaysian Journal of Medical and Biological Research" means that the author or authors retain the copyright in the paper.
This journal is granted an exclusive noncommercial reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis, etc, so long as the use is not directed at a commercial advantage or toward private monetary gain.
The author(s) can reuse the figures and tables and other information contained in their paper published by Malaysian Journal of Medical and Biological Research in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at a private monetary gain or commercial advantage.

How to Cite

Emokpae, M. A. ., & Akpologun, L. B. . (2017). The Use of Atherogenic Index of Plasma in Assessing the Potential Cardiovascular Risk among ABO Blood Groups in Sickle Cell Disease Patients. Malaysian Journal of Medical and Biological Research, 4(2), 91-96. https://doi.org/10.18034/mjmbr.v4i2.431
Crossref
Scopus
Google Scholar
Europe PMC